{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":8,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05253651\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MOUNTAINEER-03","nct_id":"NCT05253651","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mountaineer-03-nct05253651. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MOUNTAINEER-03","arms":[{"description":"Tucatinib + trastuzumab + mFOLFOX6","label":"Tucatinib Arm","type":"EXPERIMENTAL"},{"description":"Either (1) mFOLFOX6, (2) mFOLFOX6 and bevacizumab, or (3) mFOLFOX6 and cetuximab","label":"Standard of Care Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-07-03","type":"ESTIMATED"},"conditions":["Colorectal Neoplasms"],"enrollment":{"count":400,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"tucatinib","type":"DRUG"},{"name":"trastuzumab","type":"DRUG"},{"name":"bevacizumab","type":"DRUG"},{"name":"cetuximab","type":"DRUG"},{"name":"oxaliplatin","type":"DRUG"},{"name":"leucovorin","type":"DRUG"},{"name":"levoleucovorin","type":"DRUG"},{"name":"fluorouracil","type":"DRUG"}],"last_update":"2026-07-22","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","official_title":"An Open-label Randomized Phase 3 Study of Tucatinib in Combination With Trastuzumab and mFOLFOX6 Versus mFOLFOX6 Given With or Without Either Cetuximab or Bevacizumab as First-line Treatment for Subjects With HER2+ Metastatic Colorectal Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 3 years"}],"references":[{"citation":"Strickler JH, Bekaii-Saab T, Cercek A, Heinemann V, Nakamura Y, Raghav K, Siena S, Tabernero J, Van Cutsem E, Yoshino T, Ramos J, Guan X, Andre T. MOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer. Future Oncol. 2025 Feb;21(3):303-311. doi: 10.1080/14796694.2024.2441101. Epub 2024 Dec 26.","pmid":"39723627","type":"DERIVED"}],"start_date":{"date":"2022-10-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","url":"https://clinicaltrials.gov/study/NCT05253651"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mountaineer-03-nct05253651"}